OrbiMed

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Retrieved on: 
星期二, 三月 19, 2024
SVB Securities, BofA Securities, Madison Avenue, Form, Telephone, Patient, SAN, Sale, Attention, Cancer, Security (finance), Therapy, OrbiMed, Jefferies, IPSC, State Street, Jefferies Group

The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.

Key Points: 
  • The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
  • The gross proceeds from the underwritten offering and private placement are expected to be approximately $100.0 million before deducting underwriting discounts and commissions and other offering expenses.
  • BofA Securities, Jefferies, and Leerink Partners are acting as the joint bookrunning managers for the underwritten offering.
  • A final prospectus supplement relating to and describing the terms of the underwritten offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Retrieved on: 
星期一, 三月 18, 2024
DFO, McDermott Will & Emery, NESS, Cystic Fibrosis Foundation, APT, Phage therapy, Patient, Cystic fibrosis, LLP, Acquisition, Cooley LLP, Infection, OrbiMed, RBC Capital Markets, Pharmaceutical industry

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the closing of its previously announced (March 6, 2024) acquisition (the “Acquisition”) of Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.

Key Points: 
  • “We are very pleased to announce the closing of the APT acquisition, which creates a leading phage company and an advanced pipeline that includes two Phase 2 assets each aimed at treating serious infections with unmet medical need,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • “We also appreciate the continued support of leading institutional healthcare investors.
  • Haynes and Boone, LLP served as legal counsel to BiomX.
  • Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel to the placement agents.

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Retrieved on: 
星期一, 三月 18, 2024
Euronext Paris, OrbiMed, Saint-Herblain, VLA, Airline

Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024.

Key Points: 
  • Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024.
  • Maturity of this first tranche will remain in the first quarter of 2027.
  • Peter Bühler, Chief Financial Officer of Valneva, said, “We greatly appreciate the continued support from Deerfield and OrbiMed.
  • Valneva announced amendments to the terms in January 20212 and upsizing in April 20223 and August 20234.

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

Retrieved on: 
星期三, 四月 3, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, General Health, Science, Oncology, OrbiMed, Drug discovery, Patient, Cancer, Sachs, Blue Owl Capital, Protein, Medicine, Richard Driehaus, Therapy, Partner

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.

Key Points: 
  • Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.
  • The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures.
  • Concurrent with the financing, Josh Richardson, M.D., a Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, and Uwe Schoenbeck, a Partner at Canaan Partners, were named to the Board of Directors.
  • “Alterome is advancing an exciting portfolio of therapies targeting validated oncogenic drivers, with clear paths to early clinical signals,” said Dr. Josh Richardson, Managing Director within Life Sciences Investing at Goldman Sachs Alternatives.

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Retrieved on: 
星期二, 三月 26, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private equity, CDK2, Patient, Foresite Capital, Eli Lilly and Company, New Enterprise Associates, Therapy, OrbiMed, NEA, OncoMed, Pharmaceutical industry

(“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.

Key Points: 
  • (“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.
  • The total capital raised since the company’s founding in August 2022 is $347 million.
  • In conjunction with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors.
  • “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” said Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo.

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases

Retrieved on: 
星期四, 三月 21, 2024
Health, Infectious Diseases, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Farallon Capital, ARCH Venture Partners, Patient, Merck, Medicine, Investment, Therapy, OrbiMed, Machine learning, Probability, RTW, Pharmaceutical industry

Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.

Key Points: 
  • Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.
  • “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador.
  • To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science.
  • Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

Retrieved on: 
星期三, 三月 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Polaris Partners, Cell, General partnership, Venture round, RNA, Messenger, Bristol Myers Squibb, MBA, Bayer, Therapy, OrbiMed, Immune system, Eli Lilly and Company, Series, Investment, Blood, Vaccine

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.
  • The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.
  • The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
  • “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
星期二, 三月 19, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Montgomery Street, Form, Telephone, Corporation, Sale, Attention, Syndrome, Security (finance), Lexington Avenue, Suite, Form S-3, Prospectus, OrbiMed, Geron Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.
  • All of the securities in the offering are to be sold by Geron.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million.

Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference

Retrieved on: 
星期一, 三月 18, 2024
IPD, Brain, Conference, Disease, PD, CSF, Lung, OrbiMed, Traffic barrier, Parkinson's disease, LRRK2, Therapy, Safety, ACS, Kidney, Pharmaceutical industry

DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.

Key Points: 
  • DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.
  • Brenig's innovative approach to the rationally designed LRRK2 inhibitor (BT-0267) marks a significant stride in the company's mission to combat neurodegenerative diseases.
  • LRRK2, a key protein implicated in Parkinson's disease (PD), has been a challenging therapeutic target.
  • Current data highlights the superior safety profile of LRRK2 Inhibitor BT-0267 with an exceptional CSF to plasma ratio, in vivo efficacy of BT-0267 in brain and no visible lung and kidney morphological changes compared to other LRRK2 inhibitor candidates.

Expert Systems Celebrates a Milestone with Eilean Therapeutics: Initiation of First-in-Patient Trial of Balamenib, a Selective Best-in-Class Menin Inhibitor

Retrieved on: 
星期三, 三月 13, 2024
OrbiMed, AML, Drug discovery, Partnership, CBO, AI, Therapy, CTN, Safety, TGA, Expert system, Medical device

"Balamenib has a highly differentiated pre-clinical profile which indicates important advantages over molecules in the same class in safety, tolerability and feasibility of outpatient treatment," commented Bill Farley, CBO at Expert Systems.

Key Points: 
  • "Balamenib has a highly differentiated pre-clinical profile which indicates important advantages over molecules in the same class in safety, tolerability and feasibility of outpatient treatment," commented Bill Farley, CBO at Expert Systems.
  • "We are proud that our comprehensive hybrid AI-based platform has helped accelerate the development of a new promising & safe treatment for AML."
  • Supported by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, Eilean Therapeutics is committed to leading the development of innovative therapies that significantly enhance treatment outcomes in both hematologic and solid malignancies.
  • This effort is bolstered by leveraging Expert Systems' cutting-edge AI platform to speed up the discovery and development process.